Events After the End of the Reporting Period

Bayer signed an agreement on July 27, 2018, to divest the Consumer Health prescription dermatology business to LEO Pharma A/S, Ballerup, Denmark. The business will be transferred in two steps: on September 4, 2018, for the United States, and during the second half of 2019 for all other markets, subject to the satisfaction of customary closing conditions. The portfolio being divested comprises prescription brands including Advantan™, Skinoren™ and Travocort™. The purchase price amounts to €58 million for the U.S. business and €555 million for the rest of the global business, and is subject to customary purchase price adjustments.

In connection with the acquisition of Monsanto, Bayer had concluded an agreement with BASF concerning the divestment of selected Crop Science businesses. All of the transactions closed on August 1, 2018, apart from the divestment of the vegetable seed business, which closed on August 16, 2018. The total purchase price of €7.6 billion is subject to customary purchase price adjustments.

Repayment of financial liabilities

The syndicated credit facility drawn in June 2018 as bridge financing for the acquisition of Monsanto was reduced by a further US$7.9 billion in July and August 2018, mainly with the proceeds from the divestment of Crop Science businesses to BASF.

Leverkusen, August 30,
2018 Bayer Aktiengesellschaft

The Board of Management

Werner Baumann

Liam Condon

Dr. Hartmut Klusik

Kemal Malik

Wolfgang Nickl

Heiko Schipper

Dieter Weinand